Dual immunomodulator therapy with adalimumab and upadacitinib to treat recalcitrant hidradenitis suppurativa

Dual immunomodulator therapy with adalimumab and upadacitinib to treat recalcitrant hidradenitis suppurativa

Saved in:

Bibliographic Details
Main Authors:	Zahidul Islam, BA, Solbie Choi, BS, Lucy Wang, BA, Tyler M. Andriano, MD, Kristina Campton, MD
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	JAAD Case Reports
Subjects:	double-dose adalimumab dual immunomodulator therapy hidradenitis suppurativa JAK and anti-TNF therapy Janus kinase (JAK) inhibitors refractory
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512624004922
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Hypergammaglobulinemia in Hidradenitis Suppurativa Patients: A New Emerging Association
by: Martora F, et al.
Published: (2025-01-01)

Hidradenitis Suppurativa-Like Tuberculosis: A Warning for Dermatologists
by: Jose Paulo Ribeiro Junior, et al.
Published: (2025-01-01)

Secukinumab Treatment in Patients With Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study
by: Ece Erbağcı, et al.
Published: (2025-01-01)

Immediate versus Delayed Wound Closure in Hidradenitis Suppurativa Surgery: A Comparative Outcomes Study
by: Ehud Fliss, et al.

Hidradenitis Suppurativa Prevalence by Age and Race in the United States
by: Kritin K. Verma, et al.
Published: (2024-12-01)

Acquired Lymphangioma Circumscriptum of Vulva in a Patient With Hidradenitis Suppurativa: A Rare Case at a Rare Site
by: Ranju Pokharel, et al.
Published: (2025-01-01)

Demographic features, clinical characteristics, and comorbid relation in hidradenitis suppurativa: a population-based study
by: Gökhan Kaya, et al.
Published: (2025-01-01)

Clinical Epidemiology and Phenotypic Characteristics of Hidradenitis Suppurativa Disease in the Central Region of Saudi Arabia: Findings from a Cross-Sectional
by: Alotaibi H, et al.
Published: (2025-01-01)

Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association
by: Alexander D. Woods, MD, et al.
Published: (2025-03-01)

Hidradenitis secondary to nirogacestat, a recently approved desmoid tumor medication
by: Travis C. Frantz, MD, et al.
Published: (2025-03-01)

Microbial Colonization and Antibiotic Resistance Profiles in Chronic Wounds: A Comparative Study of Hidradenitis Suppurativa and Venous Ulcers
by: Florica Sandru, et al.
Published: (2025-01-01)

Response to upadacitinib monotherapy in a patient with eczematid-like pigmented purpuric dermatosis
by: Aditi Chokshi, DO, et al.
Published: (2025-02-01)

Refractory pityriasis rubra pilaris treated with abrocitinib
by: Filip Rob
Published: (2025-01-01)

Successful treatment of pyoderma gangrenosum complicated by JAK2V617F mutation-positive myelofibrosis with adalimumab and systemic steroid
by: Kyohei Shibuta, et al.
Published: (2025-01-01)

An Overview of the Skin Microbiome, the Potential for Pathogen Shift, and Dysbiosis in Common Skin Pathologies
by: Anita Smith, et al.
Published: (2025-01-01)

Bullous pemphigoid treated with baricitinib as steroid-sparing therapy for a patient with uncontrolled diabetes
by: Ji Won Heo, MD, et al.
Published: (2025-03-01)

Nursing care of an adolescent with hidradenitis suppurativa complicated with bilateral axillary skin ulcers (1例化脓性汗腺炎青少年患者双侧腋窝皮肤溃疡的护理)
by: WU Xiaokun (吴小堃), et al.
Published: (2023-12-01)

Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study
by: Stamatios Gregoriou, et al.
Published: (2025-01-01)

JAK inhibitors: a new choice for diabetes mellitus?
by: Mengjun Zhou, et al.
Published: (2025-01-01)

Baricitinib represses the myocardial fibrosis via blocking JAK/STAT and TGF-β1 pathways in vivo and in vitro
by: Renlei Feng, et al.
Published: (2025-01-01)

Adalimumab-induced optic neuropathy in a patient with Behçet’s syndrome
by: Sofia Miranda, et al.
Published: (2025-01-01)

Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022
by: Jiao Wang, et al.
Published: (2025-02-01)

Tofacitinib and budesonide treatment affect stemness and chemokine release in IBD patient-derived colonoids
by: Arun Sridhar, et al.
Published: (2025-01-01)

Tuberculosis of the tongue in a patient under treatment with adalimumab
by: Cintia Mussi Milani, et al.
Published: (2024-12-01)

Selective JAK2 pathway inhibition enhances anti-leukemic functionality in CD19 CAR-T cells
by: Kohei Mitsuno, et al.
Published: (2025-02-01)

Nootkatone Derivative Nootkatone-(E)-2-iodobenzoyl hydrazone Promotes Megakaryocytic Differentiation in Erythroleukemia by Targeting JAK2 and Enhancing JAK2/STAT3 and PKCδ/MAPK Crosstalk
by: Yang Pan, et al.
Published: (2024-12-01)

Impact in Clinical Practice of the European Medicines Agency Health Alert About the Restriction of the Use of JAK Inhibitors
by: Elisabet Castañeda-Estévez, et al.
Published: (2024-12-01)

Refractory Chronic Hand Eczema Responds to Oral Upadacitinib
by: Nada Alghamdi, et al.
Published: (2025-01-01)

Biomimetic polydopamine loaded with janus kinase inhibitor for synergistic vitiligo therapy via hydrogel microneedles
by: Chunying Li, et al.
Published: (2025-01-01)

JAK2, STAT3 Gene Polymorphisms in Turkish Patients with Behçet’s Disease
by: Darya Farhoomand Aksoy, et al.
Published: (2024-01-01)

Monocyte STAT1 phosphorylation and treatment response of JAK inhibitors in chronic nonbacterial osteomyelitis
by: Motoshi Sonoda, et al.
Published: (2025-01-01)

Case report: Generalized granuloma annulare successfully treated with baricitinib in two cases
by: Marina Yunoki, et al.
Published: (2025-01-01)

Effect of immunomodulation on cardiac remodelling and outcomes in heart failure: a quantitative synthesis of the literature
by: Navkaranbir S. Bajaj, et al.
Published: (2020-06-01)

Relation of JAK2 V617F allele burden and coronary calcium score in patients with essential thrombocythemia
by: Drofenik Ajda, et al.
Published: (2024-10-01)

Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE
by: Mi-Ae Lyu, et al.
Published: (2025-02-01)

Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn’s disease
by: Edyta Szymanska, et al.
Published: (2016-12-01)

Leflunomide-Induced Hidradenitis Suppurativa
by: Achraf Machan, et al.
Published: (2020-01-01)

A Threefold Association Between Vitiligo and Alopecia Areata: Results from a Nationwide Case-control Observational Study
by: Yonit Wohl, et al.
Published: (2025-02-01)

Mechanism of triptolide regulating proliferation and apoptosis of hepatoma cells by inhibiting JAK/STAT pathway
by: Wang Guanglian, et al.
Published: (2025-01-01)

Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
by: Carlo A. Vignoli, et al.
Published: (2025-12-01)